Nordea Investment Management AB Buys 1,493 Shares of Medpace Holdings, Inc. $MEDP

Nordea Investment Management AB lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 62,618 shares of the company’s stock after acquiring an additional 1,493 shares during the quarter. Nordea Investment Management AB’s holdings in Medpace were worth $31,487,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of MEDP. Geneos Wealth Management Inc. grew its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Employees Retirement System of Texas purchased a new stake in shares of Medpace in the 2nd quarter worth $36,000. IFP Advisors Inc grew its position in shares of Medpace by 223.3% during the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock worth $61,000 after buying an additional 134 shares in the last quarter. Hantz Financial Services Inc. grew its position in shares of Medpace by 5,075.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock worth $65,000 after buying an additional 203 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC increased its stake in shares of Medpace by 514.3% during the second quarter. Cary Street Partners Investment Advisory LLC now owns 215 shares of the company’s stock valued at $67,000 after buying an additional 180 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 1.3%

NASDAQ:MEDP opened at $616.45 on Thursday. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $626.26. The firm has a 50 day moving average of $581.78 and a 200 day moving average of $507.20. The stock has a market capitalization of $17.36 billion, a price-to-earnings ratio of 43.11, a PEG ratio of 2.04 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.36. The business had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same period in the previous year, the company earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Activity at Medpace

In other news, CEO August J. Troendle sold 59,025 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the transaction, the chief executive officer owned 774,602 shares in the company, valued at $470,787,603.56. This represents a 7.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the transaction, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 387,925 shares of company stock valued at $233,386,647 in the last ninety days. Corporate insiders own 20.30% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the subject of a number of research reports. Truist Financial set a $555.00 price objective on shares of Medpace in a research note on Monday, October 27th. Robert W. Baird set a $613.00 price target on shares of Medpace in a research report on Friday, October 24th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Finally, Mizuho set a $660.00 target price on Medpace in a research report on Friday, January 9th. Two equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $491.27.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.